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Success following allogeneic hematopoietic cell
transplantation (HSCT) is ultimately determined by
the ability to achieve sustained engraftment and im-
mune reconstitution, eradication of the abnormal or
malignant cells responsible for the patient’s disease,
and control of graft-versus-host disease (GVHD).
GVHD, an immune-mediated reaction initiated by
donor T cells in response to host alloantigen, is the
cause of significant morbidity and death in many pa-
tients. Genetic matching for HLA, the human major
histocompatibility complex (MHC), located on chro-
mosome 6p21, has for several years become well estab-
lished as a requirement for optimal HSCT outcome
[1]. Despite complete matching for all variation span-
ning 4 Mb of DNA across the MHC, acute GVHD
(aGVHD), chronic GVHD (cGVHD), and trans-
plant-related mortality (TRM) occurs in a significant
number of HLA identical sibling donor transplants.The Alloimmune Reaction
Clinical GVHD results from an alloimmune reac-
tion that occurs when immune competent donor T
cells are transplanted to an immune compromised
host and the genetic differences between donor and re-
cipient are sufficient to induce T cell activation [2].
The genetic differences responsible for an allograft
reaction encode polymorphic cellular proteins called
histocompatibility antigens [3]. The strongest histo-
compatibility antigens are encoded by the class I and
class II genes of the MHC, or HLA, but there areThe Fred Hutchinson Cancer Research Center and the
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that encode cellular peptides capable of generating sig-
nificant alloimmune responses if variation in the gene
product can be detected by T cells. These ‘‘allo’’ pep-
tides are called minor histocompatibility antigens
(mHA) [4]. Although HLA identical siblings share
50% of their genome, the mHA disparity is sufficient
to cause clinically significant aGVHD in 30% to
40% of cases. Despite HLA matching among unre-
lated donor-recipient pairs, disparity for non-MHC
mHA is greater because the recipient and donor do
not share the same parental chromosomes [5].
Pathogenesis of GVHD
The incidence, severity, and duration of GVHD
following HSCT vary substantially from patient to pa-
tient [6-11]. Differences in GVHD phenotype can re-
sult from both inherited and clinical or environmental
factors including type of disease, disease status, treat-
ment history, HLA match, age, sex of donor and pa-
tient (and sex match), and the type of conditioning
therapy administered prior to transplant [8,12,13].
High-dose cytotoxic conditioning can increase the
risk of aGVHD by causing mucosal injury, which facil-
itates translocation of endotoxin into the bloodstream,
suppressing T cell and natural killer (NK) cell-medi-
ated allograft resistance and activating antigen-pre-
senting cells (APCs) in the recipient. Within hours
after transplantation, GVHD begins with the presen-
tation of alloantigens by host dendritic cells, followed
by activation of donor T cells, which undergo clonal
expansion and migration into various lymphoid organs
and target tissues [14]. The antihost alloimmune reac-
tion is largely driven by the leakage of lipopolysaccha-
ride (LPS) across the gut wall [15], and further
amplified by multiple components of the immune sys-
tems, including NK cells, monocytes, macrophages,
and proinflammatory cytokines [16-20].
Proteomic Analysis of aGVHD and TRM
Several studies have described changes in plasma
proteins that correlate with the risk of aGVHD,e1
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though there are common discoveries among several
of these studies, there are also findings that have not in-
dependently replicated, and for this reason true posi-
tives have not been clearly defined. There remains
a great need for further and rigorously conducted stud-
ies that achieve both validation and also identification
of the clinical covariables that it must be known to fully
interpret and reliably implement biomarker data, both
proteomic and genomic, into clinical risk assessment
algorithms and preemptive therapies.
Genomic Analysis GVHD and TRM
Several studies over the last 10 years have identified
genetic polymorphisms associated with GVHD and
TRM (summarized in Table 2). Initially, these investi-
gations focused on well-known genes encoding proin-
flammatory or immune modulating cytokines
including IL1A, IL1B, IL1RN, IL6, IL10, INFG,
TGFB, and TNF [21-34]. Subsequent studies have ex-
amined additional genes for variation associated with
HSCT outcomes including CTLA4, ESR1, IL2,
IL7R, IL8, IL10RB, IL18, NOD2, and VDR [28,35-43].
Unfortunately, the results of most of these single-
center studies have not been independently validated
by others in separate patient populations. Lack of val-
idation or inconsistency in these results may be due
largely to lack of statistical power because many of
the original studies were based on relatively small
numbers (\200-300 cases). Nevertheless, these results
have been sufficiently compelling to warrant addi-
tional study. Comprehensive critical reviews of thisTable 1. Summary of Published Changes in Plasma Proteins Assoc
Protein aGVHD
IL1-RN
IL2R Miyamoto et al. 1996 [55]; Grimm et al. 1998 [56]; Foley et al
[57]; Nakamura et al. 2000 [58]; Visentainer et al. 2003 [59
Shaiegan et al. 2006 [60]; Paczesny et al. 2008 [61]
IL-6 Imamura et al. 1994 [63]
IL-8 Uguccioni et al. 1993 [64]; Paczesny et al. 2008 [61]
IL-10 Liem et al. 1998 [54]
IL-12 Nakamura et al. 2000 [58]; Mohty et al. 2005 [66]
IL-15 Sakata et al. 2001 [67]
IL-18 Nakamura et al. 2000 [58]; Fujimori et al. 2000 [68];
Shaiegan et al. 2006 [60]; Luft et al. 2007 [69]
BAFF
CD13
CCL8 Hori et al. 2008 [70]
CXCL10 Piper et al. 2007 [71]
HGF Okamoto et al. 2001 [72]; Paczesny et al. 2008 [61]
IFNG Imamura et al. 1994 [63]; Nakamura et al. 2000 [58]
TNF Holler et al. 1990 [73]; Symington et al. 1990 [74];
Imamura et al. 1994 [63]
TNFR Or 1996 et al. [75]; Kitko et al. 2008 [76]; Choi et al. 2008 [7
Paczesny et al. 2008 [61]
Syndecan-1 Seidel et al. 2003 [78]
anti-dsDNA
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versu
*Refer to original publication for additional details.research have been recently published [44,45], and
other current papers have addressed the potential
impact of developments in genomic sciences and the
opportunity for expanding HSCT outcomes research
to genome-wide discovery [1,46].
Genome-Wide Association Studies (GWAS)
The remarkable development in recent years of
methods and tools for the characterization of the entire
human genome has dramatically broadened the oppor-
tunity for the genetic analysis of disease. The recent
completion of the human genome map [47,48] and
the development of dense single nucleotide polymor-
phism (SNP) marker maps of the genome [49,50], as
well as development of massively parallel genotyping
technologies [51-53], have made it possible to screen
genes in an unbiased manner for polymorphisms that
correlate with any well-defined phenotype, disease sta-
tus, or relevant quantitative trait. This is particularly
important when considering complex traits that char-
acterize HCT complications and outcomes. Consider-
ation of the entire genome in an unbiased fashion
permits the discovery of genetic factors that would
have never been considered otherwise.
State-of-the-Art Genomic and Proteomic
Studies of GVHD and Mortality
The 3 papers that follow this Introduction are
summaries of the oral presentations that will be given
during the Genomics and Proteomics Scientific
Session of the 2009 BMT Tandem meetings. These
papers are each timely progress reports of ouriated with Acute GVHD, TRM, and Chronic GVHD*
TRM cGVHD
Liem et al. 1998 [54]
. 1998
];
Liem et al. 1998 [54];
Fujii et al. 2008 [62]
Schots et al. 2003 [65]
Liem et al. 1998 [54];
Visentainer et al. 2003 [59]
Fujii et al. 2008 [62]
Fujii et al. 2008 [62]
7];
Fujii et al. 2008 [62]
s-host disease; TRM, transplant-related mortality.






















Perez-Garcia et al. 2007 [41]
cGVHD +49/GG A/G rs231775 Azarian et al. 2007 [42]
ESR1 aGVHD MRD (108) VNTR, PvuII
and XbaI
intron 1 — — Middleton et al. 2003 [35]
FAS aGVHD MRD (160) 2670 (p) promoter A/G — Mullighan et al. 2004 [29]
IFNG aGVHD MRD (49) VNTR intron 1 na — Middleton et al. 1998 [21]
aGVHD MRD (100) 874 T/A — — Socie 2001 [23]
IL1A cGVHD MRD (115) 2899, VNTR promoter,
intron 6
C/T, allele 2 — — Cullup et al. 2003 [27] —
aGVHD
and TRM
URD(426) 2889 promoter C/T — — Mehta 2007 [34]
IL1B aGVHD MRD 2511 (p) promoter T/C rs16944 MacMillan et al. 2003[28] —
aGVHD MRD (570) 2511 (p/d) promoter C/T rs16944 — Lin 2003 [26]




MRD (107) VNTR (d) intron 2 absence of allele *2 — Rocha et al. 2002 [25] —
MRD (570) 9261 (p/d) intron 1 G/A 448341 — Lin 2003 [26]
IL2 aGVHD URD (95) 2333 (p) promoter T/G rs2069762 MacMillan Transplant 2003 [43] —
IL6 aGVHD MRD (160) 2174 (d) promoter G/C rs1800795 Mullighan et al. 2004 [29] —
aGVHD ND (93) 2174 (p/d) promoter G/C rs1800795 Karabon et al. 2005 [31] —
cGVHD 2174 promoter G/C rs1800795 Cavet et al. 1999 [22] —




MRD (570) 2174 (d) promoter G/C rs1800795 — Lin 2003 [26]
IL7R TRM MURD (75) +1237(p) cSNP A/G — Shamim et al. 2006 [40] —
TRM MRD (100) +510,+1237,+
2087,+3101
cSNPs C/T,A/G,C/T,A/G — — Shamim 2006 [40]
IL10 aGVHD MRD (49) IL10G;§ promoter — — Middleton et al. 1998 [21] —
aGVHD MRD (144) IL10/21082,
IL1021064§
promoter A/G — Cavet et al. 1999 [22] —
aGVHD MRD (100) hap¶ promoter G-C-C — Socie et al. 2001 [23] —
aGVHD MRD (993) 2592 (p) and
hap (p)¶
promoter C/A, A-T-A Lin et al. 2003 [26] —
aGVHD MRD (160) ATA hap(p) promoter — Mullighan 2004 [29]
cGVHD MRD (107) 21082*G/G(p) promoter A/G — Rocha et al. 2002 [25] —
cGVHD ATA hap(p) promoter Mullighan et al. 2004 [29] —
TRM URD (182) IL10R2§-SNP
hap (d)¶
promoter G-C-C Keen et al. 2004 [30] —
IL10RB aGVHD MRD (993) c238 (d) exon Lin et al. 2005 [37] —






















































































Holler 2004, 2006 [36,39] —
TNF aGVHD MRD (49) TNFd^,** VNTR na Middleton et al. 1998 [21]




2308 7 promoter G/A rs1800629 — Socie 2001 [23];
Lin 2003 [26];
Mullighan 2004 [29]





— Keen et al. 2004 [30] —
aGVHD & TRM MRD (160) 488 7 Mullighan et al. 2004 [29] —
TNFRII cGVHD MRD (104) codon 196 exon 6 T/G Stark et al. 2003 [79] —
VDR aGVHD and TRM MRD (88) VNTR (d) intron 8 Middleton et al. 2002 [80] —
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HCST, hematopoietic cell transplantation; VNTR, variable number tandum repeat; SNP, single nucleotide polymorphisms;
TRM, transplant-related mortality.
*Study population: MRD indicates HLA matched related donor; ND, not defined; URD, unrelated donor.
†p indicates patient; d, donor.
‡Refer to original publication(s) for additional details.
§IL10G and IL10R are a microsatellites located in and nearby the IL10 gene.
¶IL10 promoter region haplotype, positions: 21082/2819/2592.
^TNFd is a microsatellite in the TBF region.
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GVHD and TRM. The paper by Sophie Paczesny, Ja-
mie Ferrara, and team provides model example of the
rigorous 2-phase, discovery and validation, proteomic
study of changes in plasma proteins associated with the
development of aGVHD. The technology used for the
discovery phase used an antibody array containing an-
tibodies specific for 120 human proteins including
acute phase reactants, cytokines, angiogenic factors,
tumor markers, leukocyte adhesion molecules, and
metalloproteinases and their inhibitors. The papers
by Seishi Ogawa et al. and Jason Chien et al. describe
preliminary discovery data from 2 of the first large
whole genome scans performed on DNA from both
recipient and donor as a comprehensive approach to
examining genetic disparity and GVHD (Ogawa
et al.), and the association of genetic variation with
transplant outcomes including Gram-negative bacter-
emia and bronchiolitis obliterans.ACKNOWLEDGMENTS
This work was supported by grants from the
National Institutes of Health AI33484, CA015704,
CA18029, HL087690, and HL094260.REFERENCES
1. Hansen JA, Petersdorf EW, Lin MT, et al. Genetics of alloge-
neic hematopoietic cell transplantation. Role of HLA matching,
functional variation in immune response genes. Immunol Res.
2008;41:56-78.
2. Elkins WL. Cellular immunology and the pathogenesis of graft
versus host reactions (review). Prog Allergy. 1971;15:78-187.
3. Snell GD, Dausset J, Nathenson S. Histocompatibility. New York:
Academic Press; 1976.
4. Perreault C, Decary F, Brochu S, Gyger M, Belanger R, Roy D.
Minor histocompatibility antigens. Blood. 1990;76:1269-1280.
5. Martin PJ. Increased disparity for minor histocompatibility an-
tigens as a potential cause of increased GVHD risk in marrow
transplantation from unrelated donors compared with related
donors. Bone Marrow Transplant. 1991;8:217-223.
6. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A-matched sibling donors. Transplantation. 1974;18:
295-304.
7. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes
of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease: I. Diagnosis and Stag-
ing Working Group report. Biol Blood Marrow Transplant. 2005;
11:945-956.
8. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host
disease: analysis of risk factors after allogeneic marrow trans-
plantation and prophylaxis with cyclosporine and methotrexate.
Blood. 1992;80:1838-1845.
9. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus con-
ference on acute GVHD grading. BoneMarrow Transplant. 1995;
15:825-828.
10. Stewart BL, Storer B, Storek J, et al. Duration of immunosup-
pressive treatment for chronic graft-versus-host disease. Blood.
2004;104:3501-3506.11. Martin PJ, McDonald GB, Sanders JE, et al. Increasingly
frequent diagnosis of acute gastrointestinal graft-versus-host
disease after allogeneic hematopoietic cell transplantation. Biol
Blood Marrow Transplant. 2004;10:320-327.
12. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute
graft-versus-host disese after allogeneic blood stem cell trans-
plantation. Blood. 1999;94:1465-1470.
13. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host
disease after nonmyeloablative versus conventional hematopoi-
etic stem cell transplantation. Blood. 2003;102:756-762.
14. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early
events in acute graft-versus-host disease reveal sequential infil-
tration of T-cell subsets. Blood. 2005;106:1113-1122.
15. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage
priming and lipopolysaccharide-triggered release of tumor ne-
crosis factor a during graft-versus-host disease. J Exp Med.
1992;175:405-413.
16. Ferrara JLM, Deeg HJ. Graft-versus-host disease (review).
N Engl J Med. 1991;324:667-674.
17. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-
versus-host disease. Blood. 1992;80:2964-2968.
18. Jadus MR, Websic HT. The role of cytokines in graft-versus-host
reactions and disease. Bone Marrow Transplant. 1992;10:1-14.
19. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute
graft-versus-host-disease after allogeneic bone marrow trans-
plantation by tumor necrosis factor alpha (TNF alpha) release
in the course of pretransplant conditioning: role of conditioning
regimens and prophylactic application of a monoclonal antibody
neutralizing human TNF alpha (MAK 195F). Blood. 1995;86:
890-899.
20. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute
graft-versus-host disease (review). Transplantation. 1997;64:
553-558.
21. Middleton PG, Taylor PRA, Jackson G, Proctor SJ,
Dickinson AM. Cytokine gene polymorphisms associating
with severe acute graft-versus-host disease in HLA-identical
sibling transplants. Blood. 1998;92:3943-3948.
22. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM,
Dickinson AM. Recipient tumor necrosis factor-alpha and inter-
leukin-10 gene polymorphisms associate with early mortality
and acute graft-versus-host disease severity in HLA-matched
sibling bone marrow transplants. Blood. 1999;94:3941-3946.
23. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical
factors predict the development of graft-versus-host disease after
allogeneic hematopoietic stem cell transplantation. Transplanta-
tion. 2001;72:699-706.
24. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J,
Middleton PG. Donor interleukin 1 receptor antagonist geno-
type associated with acute graft-versus-host disease in human
leucocyte antigen-matched sibling allogeneic transplants. Br J
Haematol. 2001;113:807-813.
25. Rocha V, Franco RF, Porcher R, et al. Host defense and inflam-
matory gene polymorphisms are associated with outcomes after
HLA-identical sibling bone marrow transplantation. Blood.
2002;100:3908-3918.
26. Lin M-T, Storer B, Martin PJ, et al. Relation of an interleukin-
10 promoter polymorphism to graft-versus-host disease and sur-
vival after hematopoietic-cell transplantation. N Engl J Med.
2003;349:2201-2210.
27. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG.
Polymorphisms of interleukin-1alpha constitute independent
risk factors for chronic graft-versus-host disease after allogeneic
bone marrow transplantation. Br J Haematol. 2003;122:778-787.
28. MacMillan ML, Radloff GA, Defor TE, Weisdorf DJ,
Davies SM. Interleukin-1 genotype and outcome of unrelated
donor bone marrow transplantation. Br J Haematol. 2003;121:
597-604.
29. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immuno-
genetic polymorphisms and the risk of complications after allo-
geneic hemopoietic stem-cell transplantation. Transplantation.
2004;27:587-596.
e6 Biol Blood Marrow Transplant 15:1-7, 2009J. A. Hansen30. Keen LJ, Defor TE, Bidwell JL, Davies SM, Bradley BA,
Hows JM. Interleukin-10 and tumor necrosis factor alpha
region haplotypes predict transplant-related mortality after
unrelated donor stem cell transplantation. Blood. 2004;103:
3599-3602.
31. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K,
Lange A. IL-6 and IL-10 promoter gene polymorphisms of pa-
tients and donors of allogeneic sibling hematopoietic stem cell
transplants associate with the risk of acute graft-versus-host
disease. Hum Immunol. 2005;66:700-710.
32. Seo KW, Kim DH, Sohn SK, et al. Protective role of inter-
leukin-10 promoter gene polymorphism in the pathogenesis
of invasive pulmonary aspergillosis after allogeneic stem
cell transplantation. Bone Marrow Transplant. 2005;36:1089-
1095.
33. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The
presence of IFNG 3/3 genotype in the recipient associates
with increased risk for Epstein-Barr virus reactivation after allo-
geneic haematopoietic stem cell transplantation. Br J Haematol.
2006;132:326-332.
34. Mehta PA, Eapen M, Klein JP, et al. Interleukin-1 alpha geno-
type and outcome of unrelated donor haematopoietic stem cell
transplantation for chronic myeloid leukaemia. Br J Haematol.
2007;137:152-157.
35. Middleton PG, Norden J, Cullup H, et al. Oestrogen receptor
alpha gene polymorphism associates with occurrence of graft-
versus-host disease and reduced survival in HLA-matched sib-
allo BMT. Bone Marrow Transplant. 2003;32:41-47.
36. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient
NOD2/CARD15 mutations associate with transplant-related
mortality and GvHD following allogeneic stem cell transplanta-
tion. Blood. 2004;104:889-894.
37. Lin M-T, Storer B, Martin PJ, et al. Genetic variation in the
IL-10 pathway modulates severity of acute graft-versus-host
disease following hematopoietic cell transplantation: synergism
between IL-10 genotype of patient and IL-10 receptor b geno-
type of donor. Blood. 2005;106:3995-4001.
38. Cardoso SM, Defor TE, Tilley LA, Bidwell JL, Weisdorf DJ,
MacMillan ML. Patient interleukin-18 GCG haplotype associ-
ates with improved survival and decreased transplant-related
mortality after unrelated-donor bone marrow transplantation.
Br J Haematol. 2004;126:704-710.
39. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance
of NOD2/CARD15 variants in HLA-identical sibling hemato-
poietic stem cell transplantation: effect on long term outcome
is confirmed in 2 independent cohorts and may be modulated
by the type of gastrointestinal decontamination. Blood. 2006;
107:4189-4193.
40. Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms
in the genes encoding human interleukin-7 receptor-alpha: prog-
nostic significance in allogeneic stem cell transplantation. Bone
Marrow Transplant. 2006;37:485-491.
41. Perez-Garcia A, de la CR, Roman-Gomez J, et al. CTLA-4
polymorphisms and clinical outcome after allogeneic stem cell
transplantation from HLA-identical sibling donors. Blood.
2007;110:461-467.
42. Azarian M, Busson M, Lepage V, et al. Donor CTLA-4 149
A/G*GG genotype is associated with chronic GVHD after
HLA-identical haematopoietic stem-cell transplantations. Blood.
2007;110:4623-4624.
43. MacMillan ML, Radloff GA, Kiffmeyer WR, Defor TE,
Weisdorf DJ, Davies SM. High-producer interleukin-2 geno-
type increases risk for acute graft-versus-host disease after unre-
lated donor bone marrow transplantation. Transplantation. 2003;
76:1758-1762.
44. Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem
cell transplantation: can our genes predict clinical outcome?
(review). Expert Rev Mol Med. 2007;9:1-19.
45. Mullighan CG, Bardy PG. New directions in the genomics of al-
logeneic hematopoietic stem cell transplantation. Biol Blood
Marrow Transplant. 2007;13:127-144.46. Mullally A, Ritz J. Beyond HLA: the significance of genomic
variation for allogeneic hematopoietic stem cell transplantation.
Blood. 2007;109:1355-1362.
47. Lander ES, Linton LM, Birren B, et al. Initial sequencing and
analysis of the human genome. Erratum appears in Nature
2001 Aug 2;412(6846):565. Note: Szustakowki, J [corrected to
Szustakowski, J]. Nature. 2001;409:860-921.
48. Venter JC, Adams MD, Myers EW, et al. The sequence of the
human genome [erratum appears in Science 2001 Jun
5;292(5523):1838]. Science. 2001;291:1304-1351.
49. Miller RD, Phillips MS, Jo I, et al. High-density single-nucleo-
tide polymorphism maps of the human genome. Genomics. 2005;
86:117-126.
50. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of
haplotype blocks in the human genome. Science. 2002;296:
2225-2229.
51. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000
SNPs on a pair of oligonucleotide arrays. Nat Methods. 2004;1:
109-111.
52. Steemers FJ, Chang W, Lee G, Barker DL, Shen R,
Gunderson KL. Whole-genome genotyping with the single-
base extension assay. Nat Methods. 2006;3:31-33.
53. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A
genome-wide scalable SNP genotyping assay using microarray
technology. Nat Genet. 2005;37:549-554.
54. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine
levels after HLA-identical bone marrow transplantation. Trans-
plantation. 1998;66:863-871.
55. Miyamoto T, Akashi K, Hayashi S, et al. Serum concentration of
the soluble interleukin-2 receptor for monitoring acute graft-
versus-host disease. Bone Marrow Transplant. 1996;17:185-190.
56. Grimm J, Zeller W, Zander AR. Soluble interleukin-2 receptor
serum levels after allogeneic bone marrow transplantations as
a marker for GVHD. Bone Marrow Transplant. 1998;21:29-32.
57. Foley R, Couban S, Walker I, et al. Monitoring soluble interleu-
kin-2 receptor levels in related and unrelated donor allogenic
bone marrow transplantation. Bone Marrow Transplant. 1998;
21:769-773.
58. Nakamura H, Komatsu K, Ayaki M, et al. Serum levels of soluble
IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with
acute graft-versus-host disease after allogeneic bone marrow
transplantation. J Allergy Clin Immunol. 2000;106:S45-S50.
59. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine
levels and acute graft-versus-host disease after HLA-identical
hematopoietic stem cell transplantation. Exp Hematol. 2003;31:
1044-1050.
60. Shaiegan M, Iravani M, Babaee GR, Ghavamzadeh A. Effect of
IL-18 and sIL2R on aGVHD occurrence after hematopoietic
stem cell transplantation in some Iranian patients. Transpl
Immunol. 2006;15:223-227.
61. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel
for acute graft versus host disease. Blood. 9999; prepublished
online October 2, 2008; DOI 10.1182/blood-2008-07-167098-
62. Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed
pediatric-extensive chronic graft-versus-host disease: a report
from the Children’s Oncology Group. Blood. 2008;111:3276-
3285.
63. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine
levels in bone marrow transplantation: synergistic interaction
of interleukin-6, interferon-gamma, and tumor necrosis factor-
alpha in graft-versus-host disease. Bone Marrow Transplant.
1994;13:745-751.
64. Uguccioni M, Meliconi R, Nesci S, et al. Elevated interleukin-8
serum concentrations in beta-thalassemia and graft-versus-host
disease. Blood. 1993;81:2252-2256.
65. Schots R, Kaufman L, Van RI, et al. Proinflammatory cytokines
and their role in the development of major transplant-related
complications in the early phase after allogeneic bone marrow
transplantation. Leukemia. 2003;17:1150-1156.
66. Mohty M, Blaise D, Faucher C, et al. Inflammatory cytokines
and acute graft-versus-host disease after reduced-intensity
Biol Blood Marrow Transplant 15:1-7, 2009 e7Genomic and Proteomic Analysis of Allogeneic HCT Outcomeconditioning allogeneic stem cell transplantation. Blood. 2005;
106:4407-4411.
67. Sakata N, Yasui M, Okamura T, Inoue M, Yumura-Yagi K,
Kawa K. Kinetics of plasma cytokines after hematopoietic
stem cell transplantation from unrelated donors: the ratio of
plasma IL-10/sTNFR level as a potential prognostic marker in
severe acute graft-versus-host disease. Bone Marrow Transplant.
2001;27:1153-1161.
68. Fujimori Y, Takatsuka H, Takemoto Y, et al. Elevated interleu-
kin (IL)-18 levels during acute graft-versus-host disease after
allogeneic bone marrow transplantation. Br J Haematol. 2000;
109:652-657.
69. Luft T, Conzelmann M, Benner A, et al. Serum cytokeratin-18
fragments as quantitative markers of epithelial apoptosis in
liver and intestinal graft-versus-host disease. Blood. 2007;110:
4535-4542.
70. Hori T, Naishiro Y, Sohma H, et al. CCL8 is a potential molec-
ular candidate for the diagnosis of graft-versus-host disease.
Blood. 2008;111:4403-4412.
71. Piper KP, Horlock C, Curnow SJ, et al. CXCL10-CXCR3 in-
teractions play an important role in the pathogenesis of acute
graft-versus-host disease in the skin following allogeneic stem-
cell transplantation. Blood. 2007;110:3827-3832.
72. Okamoto T, Takatsuka H, Fujimori Y, Wada H, Iwasaki T,
Kakishita E. Increased hepatocyte growth factor in serum in
acute graft-versus-host disease. Bone Marrow Transplant. 2001;
28:197-200.
73. Holler E, Kolb HJ, Mo¨ller A, et al. Increased serum levels of
tumor necrosis factor a precede major complications of bone
marrow transplantation. Blood. 1990;75:1011-1016.74. Smith JH, Rotterdam HZ, Christie JD, et al. Specialty confer-
ence on infectious and inflammatory diseases. Mod Pathol.
1990;3:223-233.
75. Or R, Kalinkovich A, Nagler A, et al. Soluble tumor necrosis
factor (sTNF) receptors: a possible prognostic marker for
bone marrow transplantation-related complications. Cytokines
Mol Ther. 1996;2:243-250.
76. Kitko CL, Paczesny S, Yanik G, et al. Plasma elevations of tumor
necrosis factor-receptor-1 at day 7 postallogeneic transplant
correlate with graft-versus-host disease severity and overall sur-
vival in pediatric patients. Biol BloodMarrow Transplant. 2008;14:
759-765.
77. Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor
necrosis factor receptor 1 levels in the first week after myeloabla-
tive allogeneic transplantation correlates with severity and
incidence of GVHD and survival. Blood. 2008;112:1539-1542.
78. Seidel C, Ringden O, Remberger M. Increased levels of synde-
can-1 in serum during acute graft-versus-host disease. Trans-
plantation. 2003;76:423-426.
79. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ,
Middleton PG. Tumour necrosis factor receptor type II 196M/
R genotype correlates with circulating soluble receptor levels in
normal subjects and with graft-versus-host disease after sibling
allogeneic bone marrow transplantation. Transplantation. 2003;
76:1742-1749.
80. Middleton PG, Cullup H, Dickinson AM, et al. Vitamin D
receptor gene polymorphism associates with graft-versus-host
disease and survival in HLA-matched sibling allogeneic bone
marrow transplantation. Bone Marrow Transplant. 2002;30:
223-228.
